# Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct07801820` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07801820](<https://clinicaltrials.gov/study/NCT07801820>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07801820

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 240 participants.

## Technical summary

Registry record NCT07801820. Randomized; double masking; primary purpose treatment. Start 2026-06-23 (actual); primary completion 2027-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 240 participants (planned count; ClinicalTrials.gov record NCT07801820, source copy `cardio:ctgov-nct07801820-2026-09-09`, retrieved 2026-10-26)
- Started: 2026-06-23 (actual) (ClinicalTrials.gov record NCT07801820, source copy `cardio:ctgov-nct07801820-2026-09-09`, retrieved 2026-10-26)
- Primary completion: 2027-03 (anticipated) (ClinicalTrials.gov record NCT07801820, source copy `cardio:ctgov-nct07801820-2026-09-09`, retrieved 2026-10-26)
- Completion: 2027-03 (anticipated) (ClinicalTrials.gov record NCT07801820, source copy `cardio:ctgov-nct07801820-2026-09-09`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07801820, source copy `cardio:ctgov-nct07801820-2026-09-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07801820-2026-09-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus
- Condition: Type 2 Diabetes Mellitus (T2DM)
- Intervention (Drug): MWN109 1
- Intervention (Drug): MWN109 2
- Intervention (Drug): MWN109 3
- Intervention (Drug): MWN109 4
- Intervention (Drug): Placebo
- Intervention (Drug): Semaglutide Tablets
- Lead sponsor: Shanghai Minwei Biotechnology Co., Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 1bb7f9d13a4a02d2f74ebe7b4647a247fa8e86bf2d73b3881809962ef01c4c3e
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
